title: Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.
abstract: OBJECTIVE
  Visceral leishmaniasis (VL) is a common complication in AIDS patients living in Leishmania-endemic areas. Although antiretroviral therapy has changed the clinical course of HIV infection and its associated illnesses, the prevention of VL relapses remains a challenge for the care of HIV and Leishmania co-infected patients. This work is a systematic review of previous studies that have described predictors of VL relapse in HIV-infected patients.
  
  
  METHODS
  We searched the electronic databases of MEDLINE, LILACS, and the Cochrane Central Register of Controlled Trials. Studies were selected if they included HIV-infected individuals with a VL diagnosis and patient follow-up after the leishmaniasis treatment with an analysis of the clearly defined outcome of prediction of relapse.
  
  
  RESULTS
  Eighteen out 178 studies satisfied the specified inclusion criteria. Most patients were males between 30 and 40 years of age, and HIV transmission was primarily via intravenous drug use. Previous VL episodes were identified as risk factors for relapse in 3 studies. Two studies found that baseline CD4+ T cell count above 100 cells/mL was associated with a decreased relapse rate. The observation of an increase in CD4+ T cells at patient follow-up was associated with protection from relapse in 5 of 7 studies. Meta-analysis of all studies assessing secondary prophylaxis showed significant reduction of VL relapse rate following prophylaxis. None of the five observational studies evaluating the impact of highly active antiretroviral therapy use found a reduction in the risk of VL relapse upon patient follow-up.
  
  
  CONCLUSIONS
  SOME PREDICTORS OF VL RELAPSE COULD BE IDENTIFIED: a) the absence of an increase in CD4+ cells at follow-up; b) lack of secondary prophylaxis; and c) previous history of VL relapse. CD4+ counts below 100 cells/mL at the time of primary VL diagnosis may also be a predictive factor for VL relapse.
authors.affiliation: Post-Graduate Program in Health Sciences, René Rachou Institute, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil. glauciacota@uol.com.br
authors.forename: Gláucia F
authors.initials: GF
authors.lastname: Cota
authors.forename: Marcos R
authors.initials: MR
authors.lastname: de Sousa
authors.forename: Ana
authors.initials: A
authors.lastname: Rabello
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D018890:Chemoprevention / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000175:diagnosis*; D008297:Male; D012008:Recurrence; D012307:Risk Factors